Japanese drugmaker Eisai and US-based Biogen have been working together on advancing research in the space of Alzheimer’s for nearly a decade. Finally, the FDA, granted the fruits of that labor, Leqembi, its blessing for intravenous use. This marks the first approved treatment that can slow the progression of Alzheimer’s.
Yeah, any news like this is heartening but I always take it with a large grain of salt. I’ve got family member affected by Alzheimer’s so it really hits home.